Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01163227 · ClinicalTrials.gov registry record · Phase 2
Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT01163227 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 57 participants.
The verdict
NCT01163227, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
This PoC study is designed to assess the cognitive effects of doses of AQW051 in patients with chronic stable schizophrenia.
Interventions
- DRUG Placebo (single and multiple doses)
- DRUG AQW051 2 mg (single and multiple doses)
- DRUG AQW051 15mg (single and multiple doses)
- DRUG AQW051 100mg (single dose), and 50mg (multiple doses)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2010-05 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01163227
The ClinicalTrials.gov registry entry for NCT01163227 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo (single and multiple doses) is the first listed.
NCT01163227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01163227 about?
NCT01163227 is a clinical study titled "Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia". This PoC study is designed to assess the cognitive effects of doses of AQW051 in patients with chronic stable schizophrenia.
What is the current status of trial NCT01163227?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2010-05. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01163227?
The interventions under investigation include: Placebo (single and multiple doses) (DRUG), AQW051 2 mg (single and multiple doses) (DRUG), AQW051 15mg (single and multiple doses) (DRUG), AQW051 100mg (single dose), and 50mg (multiple doses) (DRUG).
Who is sponsoring clinical trial NCT01163227?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.